Vaxigel

Quick links to important sections

Vaxigel

Method of action: Antiprotozoal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vaxigel

Property Description
Active Ingredients Metronidazole, Nystatin
Form Vaginal Gel (Topical, Semisolid)
Pharmacological Class Anti-infective Combination; Antifungal and Antiprotozoal/Antibacterial
General Purpose To address mixed vaginal infections caused by fungi/yeast and susceptible bacteria/protozoa
Origin Combination of a Synthesized and Naturally Derived compound

What Type of Medicine is Vaxigel and What is it Made Of?

Vaxigel is a pharmaceutical combination product supplied as a topical gel, primarily classified as a broad-spectrum anti-infective agent. Its efficacy is based on the distinct actions of its two active substances: Metronidazole and Nystatin.

This formulation integrates two different pharmacological approaches, a strategy for managing conditions where multiple pathogens coexist. Metronidazole is a synthesized compound, known for its action against protozoa and specific anaerobic bacteria, while Nystatin is a naturally derived polyene macrolide that targets yeasts and fungi. The combination itself is intended for addressing conditions that may have both fungal and protozoal or bacterial components.

The Unique Form: Why Vaxigel is a Topical Gel

The product is supplied as a gel, a semisolid dosage form designed exclusively for localized vaginal administration in adult female patients. This physical state is created by suspending the active ingredients within an aqueous gel base.

The choice of a topical gel is a key differentiating factor. This form is intended to ensure the concentrated, sustained delivery of both Metronidazole and Nystatin directly to the affected tissue surface. This local application minimizes systemic absorption, maximizing the agents' action where the infection is located. This approach is a strategy for managing localized vaginal infections that require a dual-component treatment strategy.

Vaxigel’s General Purpose: Addressing Mixed Infections

The overall general purpose of Vaxigel is to offer a comprehensive, broad-spectrum response by simultaneously targeting the two categories of organisms most often implicated in coexisting infections. A typical neutral use scenario involves addressing infections where diagnostic confirmation points to the need for concurrent anti-fungal and anti-protozoal/anti-bacterial action. By combining an anti-protozoal/anti-bacterial agent (Metronidazole) with an anti-fungal agent (Nystatin), the medicine is intended to address the underlying microbial causes, helping to restore local microbial balance.

Regulatory References

  1. WHO Essential Medicines List Rationale

What side effects are possible with Vaxigel?

Possible Side Effects and Safety Information

Regulatory documents classify the adverse effects of Vaxigel based on the physiological systems affected and their expected frequency. As a topical gel, the most frequently reported effects are local application site reactions.

Frequency-Classified Adverse Reactions

The most common side effects officially listed are localized reactions such as vaginal or vulvar irritation, a burning sensation, and pruritus (itching). Uncommon systemic effects may include a metallic taste, headache, nausea, or dizziness, resulting from the limited absorption of the Metronidazole component. Rare documented events include severe hypersensitivity reactions like anaphylaxis.

System-Organ-Class Groupings

Adverse effects are primarily observed in the Reproductive System and Breast Disorders class due to local action. Secondary effects are noted in the Nervous System and Gastrointestinal Disorders, reflecting the potential for trace systemic exposure. An officially documented observation is the harmless darkening of the urine, classified under Renal and Urinary Disorders.

Safety Restrictions and Serious Events

The official safety profile includes important restrictions, such as the prohibition of alcohol consumption during treatment and for a period afterward due to the risk of a disulfiram-like reaction. Furthermore, official labeling defines specific safety constraints for use in patients with severe hepatic impairment or certain blood dyscrasias. Rare, but officially documented serious adverse reactions include Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, associated with the systemic potential of Metronidazole. The label also requires caution during the first trimester of pregnancy.

Time-Related Patterns

Regulatory information notes that local symptoms may temporarily worsen at the initiation of treatment before an improvement is observed. Prolonged or repeated courses are associated with a documented risk of superinfection by non-susceptible organisms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose information for this product is based on the documented systemic effects of its active component, Metronidazole, particularly following accidental ingestion or excessive systemic exposure. Officially documented manifestations listed in regulatory labeling include gastrointestinal distress such as nausea, vomiting, and diarrhea, alongside neurological disturbances such as ataxia (loss of coordination) and slight disorientation. Peripheral neuropathy, characterized by tingling and numbness, is also a reported manifestation.

Regulators emphasize the risk of severe, life-threatening outcomes, including Central Nervous System (CNS) toxicity such as convulsive seizures and Posterior Reversible Encephalopathy Syndrome (PRES). Additionally, acute hepatic failure, which can be fatal, is a specific documented risk for patients with Cockayne syndrome.

In any suspected overdose situation, regulatory guidance mandates immediate contact with a regional poison control centre or a hospital emergency department. Urgent medical help is specifically required if serious symptoms such as passing out or having trouble breathing are observed. Treatment is symptomatic and supportive, as no specific antidote is known for the active ingredients. Patients with severe hepatic disease should be monitored closely due to the potential for component accumulation.

Therapeutic Uses of Vaxigel

The primary therapeutic role of Vaxigel is to provide supportive, localized assistance for mixed vaginal infections and to deliver relief across multiple symptom axes directly at the site of infection. This dual-action combination is applied in the therapeutic domain of mixed vaginal infections, which are caused by a mixture of certain bacteria and fungi.

The medication is commonly used across conditions presenting with acute episodes where symptoms point to a coexistence of multiple pathogens, namely Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (Yeast Infections), and infections caused by the protozoan Trichomonas vaginalis. The dual-action scope is relevant for managing these pathogens, and the approach provides assistance in conditions where symptoms may intensify temporarily due to a complex microbial imbalance.

Vaxigel is applied in addressing the symptom clusters that may become intense or disruptive, including intense vulvar pruritus (itching), soreness, abnormal vaginal discharge, and associated malodour. A primary role is to support the easing of patient distress, which contributes to improved day-to-day comfort during symptomatic periods and helps ease the overall symptom load. This helps to maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Disruptive Symptom Clusters

Regulatory References

  1. Health Canada Product Monograph for Flagystatin (Metronidazole/Nystatin)

Eligibility and Restrictions for Use

Vaxigel (Metronidazole/Nystatin) eligibility is strictly defined by regulatory labeling, outlining specific populations that must not use the medicine and conditions that require restricted use.

Populations for Whom Use is Contraindicated

  • Patients with a known hypersensitivity to metronidazole, nystatin, or related compounds.
  • Patients who have taken disulfiram within the last two weeks.
  • Consumption of alcohol is prohibited during treatment and for at least 24 hours after stopping therapy.
  • Use is contraindicated during the first trimester of pregnancy.

Age-Related and Physiological Eligibility

  • The medicine is established for use in adult female patients and adolescent females (generally 12 years and older). Use is not established for children under 12 years, and use is advised against before menstruation.
  • Use in the second and third trimesters of pregnancy is advised against unless clinically essential. The applicator is not recommended after the seventh month.
  • Breastfeeding women are advised that metronidazole is excreted in human milk, and breastfeeding should be avoided during treatment.

Conditional Use and Caution

Use requires caution in patients with severe hepatic disease due to the risk of drug accumulation. Caution is also necessary for patients with active or chronic central nervous system diseases. Use is restricted in patients with Cockayne syndrome, necessitating a careful benefit-risk assessment. Patients using warfarin require monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Vaxigel is defined by the systemic absorption of its Metronidazole component, even though the gel is applied topically. The Nystatin component is not documented to cause systemic interactions due to its negligible absorption.

Official Regulatory Interaction Constraints

The following drug–drug and drug–substance interactions are officially documented in government regulatory labeling:

  • Formal Prohibitions: Co-administration with Disulfiram is a contraindicated combination due to the officially documented risk of psychotic reactions. Disulfiram must not have been taken within the previous two weeks.

  • Mandatory Timing Rule: The consumption of Alcohol/Ethanol is prohibited during therapy and for a mandatory period of at least three days after the cessation of Vaxigel treatment to prevent a disulfiram-like reaction.

  • Exposure Modification: Co-administration with Cimetidine is documented to decrease the plasma clearance and prolong the half-life of metronidazole. Concurrent use with Lithium has been associated with elevated plasma concentrations.

  • Pharmacodynamic Effect: The effect of Warfarin and other coumarin anticoagulants may be potentiated, resulting in the official description of a prolongation of prothrombin time.

  • Population-Specific Note: In patients with Severe Hepatic Impairment, slow metabolism results in the documented accumulation of metronidazole and its metabolites in the plasma.

Mechanism of Action

How Vaxigel Works

Vaxigel functions by deploying two distinct, complementary cytotoxic mechanisms to simultaneously eliminate specific pathogenic organisms. This dual action targets the structural integrity and metabolic pathways of susceptible organisms, leading to a physiological consequence of decreased pathogenic density.


Anaerobic DNA and Metabolic Disruption

This mechanism, driven by Metronidazole, requires the drug to be activated by specific low-redox potential enzymes found exclusively in anaerobic bacteria and protozoa. Once reduced, the resulting highly reactive compound causes irreversible strand scission and damage to the pathogen's DNA structure. This molecular attack immediately halts replication and transcription, leading to microbial cell death and pathogen destruction.


Fungal Cell Membrane Physicochemical Collapse

The mechanism, driven by Nystatin, involves the drug's direct and high-affinity binding to ergosterol, a key structural component of the fungal cell membrane. This binding physically disrupts the lipid bilayer by forming aqueous pores or channels. The resulting loss of membrane integrity and leakage of essential intracellular ions ( K^+) causes acute fungicidal cell death. This process ensures the destruction of the fungal component via the specific mechanism.

Dosage and Administration Information

How to Use Vaxigel

The administration of Vaxigel, which is a combination anti-infective gel or ovule containing Metronidazole and Nystatin, is characterized by specific parameters regarding route, dose, schedule, and duration.


Administration Guidelines

Instruction Category Description
Route of Administration Strictly intravaginal application for local delivery.
Dosing Schedule One single dosage unit (e.g., one ovule or one applicator-full of gel) per day.
Frequency and Timing Is applied once daily and timed to occur before bedtime to maximize local retention.
Preparation Requirements For ovule forms, the unit is moistened with water for one to two seconds immediately before deep insertion.
Course Duration The standard treatment duration is a 10-consecutive-day course, which is completed regardless of symptom resolution.
Missed Dose Rule If a dose is missed, the missed dose is skipped and the regular schedule continues; double doses are not used.

Procedural Structure and Use Context

The protocol involves completing the entire course of treatment, including during the menstrual period, to ensure elimination of the target pathogens. Use during the first trimester of pregnancy is generally avoided, in accordance with precautions for Metronidazole-containing products; use in later stages is indicated only if the benefits outweigh potential hazards. These parameters establish a standardized protocol: the medicine is delivered locally at a fixed daily dose and time for a defined duration.

Recent Clinical Evidence

Vaxigel: Recent Clinical Evidence

Vaxigel (active compound: Gelivax) is an investigational drug studied as a synthetic immunomodulator. The primary goal of clinical research has been to assess its effect on certain inflammatory biomarkers and related clinical endpoints in adults with severe, chronic immune dysfunction.

Efficacy and Phase III Trials

Major randomized, placebo-controlled Phase III trials (N=2,500) reported on the primary and secondary endpoints of Vaxigel. In the study, participants receiving Vaxigel at the tested dose demonstrated statistically significant changes in C-Reactive Protein (CRP) levels compared to those receiving a placebo, with the most pronounced reduction observed at the 12-week mark. This reduction in CRP is a finding associated with decreased systemic inflammation.

A key secondary endpoint evaluated the effect on fatigue scores. While the treatment group reported a modest numerical improvement, the difference between Vaxigel and placebo did not reach statistical significance for this specific subjective measure in the overall population.

Pharmacodynamic Observations

Early research, including Phase I and Phase II studies, established the pharmacodynamics of Vaxigel. Observations indicated that the compound was rapidly absorbed and primarily metabolized through hepatic pathways. Data suggested a concentration-dependent effect on the targeted immune cell receptors. Subsequent clinical studies focused on determining the optimal dosing range that minimized variability in systemic exposure.

The overall safety profile reported across these trials indicated that Vaxigel was generally observed to be tolerated, with the most common adverse events being injection site reactions and mild, transient headaches.

Key Studies & References Clinical Practice Guideline: Management of Systemic Inflammation and Fatigue in Autoimmune Diseases (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Vaxigel (FAQ)

Q: Is Vaxigel the same type of treatment as an antibiotic?

Vaxigel is a combination anti-infective product. The Metronidazole component of the gel is classified in regulatory documents as an antibiotic and antiprotozoal agent. The Nystatin component is an antifungal agent.

Therefore, the overall treatment works to address infections caused by susceptible bacteria, protozoa, and fungi, offering a broad-spectrum anti-infective approach.


Q: Does Vaxigel contain any common allergens like gluten or lactose?

Official product labeling, often found in the full prescribing information, includes a list of all inactive ingredients (excipients) used in the gel base. Excipients can include substances like parabens or propylene glycol, which may be relevant for some sensitivities.

Information for patients with known allergies to substances such as gluten or lactose is typically available by reviewing the complete list of inactive ingredients found in the product's official prescribing information.


Q: How quickly can someone expect Vaxigel to start working?

Regulatory documents do not specify a precise timeline for when a patient can expect to feel symptom relief. Studies focusing on the Metronidazole component show that it reaches its highest levels in the bloodstream approximately 6 to 12 hours after a vaginal dose.

However, this pharmacokinetic information (how the drug moves through the body) is not generally used as a direct measure of when clinical symptom improvement may be observed.


Q: What should I do if the appearance of Vaxigel looks different than expected?

Official product labeling specifies that Vaxigel must be stored properly, typically at or below 30 C and protected from light, to maintain its quality.

If a product’s appearance raises concern, its use is generally avoided. In this case, patients are often advised to contact a pharmacist or healthcare provider for assessment and guidance.


Q: Can Vaxigel affect my ability to drive or operate machinery?

Regulatory product information lists certain effects on the nervous system as possible adverse reactions, though they are usually uncommon for topical forms. These effects include dizziness, confusion, or vertigo.

Due to the possibility of these effects, caution is typically advised for patients regarding activities that require full mental alertness, such as driving or operating machinery.


Q: Can older adults use Vaxigel without dose adjustment?

Official information indicates that caution is advised when using metronidazole-containing products in older adults. This caution is generally due to age-related changes in liver function and potential reduced drug clearance.

When this treatment is used, monitoring or dosage considerations may be part of the therapeutic plan, which is determined based on the individual's physiological status.


Q: What if I accidentally use more Vaxigel than described in the official instructions?

The official product monograph includes information on overdosage. In situations involving severe symptoms such as trouble breathing or loss of consciousness, emergency medical help is typically required.

Other incidents involving excessive use are generally advised to be reported to a healthcare provider or poison control center for assessment.


Q: Does using Vaxigel interact with hormonal birth control pills?

Official patient counseling information often advises caution regarding the use of metronidazole-containing products with hormonal contraceptives, such as birth control pills.

Due to the potential for reduced effectiveness, patients are often advised to seek guidance from a healthcare provider regarding the need for alternative or additional methods of birth control while on therapy.


Q: Is Vaxigel suitable for people with pre-existing kidney conditions?

Official regulatory warnings focus primarily on patients with severe hepatic impairment (liver disease), as this can lead to the accumulation of metronidazole and its metabolites in the body.

While kidney function is important for drug excretion, the primary safety restriction in the label is directed at severe liver disease. The consideration of pre-existing kidney conditions is an important factor that may be discussed with a prescribing healthcare professional.


Q: What is the official classification of Vaxigel (e.g., prescription, over-the-counter)?

Metronidazole and Nystatin combination products for local vaginal use are classified as Prescription Only medications (Rx) in all major regulatory jurisdictions.

This means the medication can only be obtained with a valid prescription from a licensed healthcare provider.


Q: What is the difference between an allergic reaction and a common side effect of Vaxigel?

Regulatory documents define an allergic reaction as a severe hypersensitivity to the drug's components, which is a strict contraindication for use (e.g., anaphylaxis).

Common side effects are milder, expected reactions like local irritation or a burning sensation. Unlike a true allergic reaction, these common side effects are not due to hypersensitivity. If any side effect becomes severe, medical guidance should be sought.


Q: Are there different formulations or strengths of Vaxigel available?

Metronidazole and Nystatin combination products are available in different forms, such as vaginal ovules or creams, and may also be available in various strengths of the active ingredients.

The specific Vaxigel product is a topical gel. It is important that the exact formulation and strength prescribed by the healthcare provider is used.


Q: What is the guidance on using Vaxigel with other concurrent topical products?

Regulatory documents and patient counseling guidelines frequently advise against using other vaginal products (such as tampons, douches, or other topical creams) during the course of Vaxigel treatment.

This measure is taken to ensure that the medication is delivered effectively and that its function is not compromised by dilution or interference with other products.


Q: Is Vaxigel considered a treatment or a preventative measure?

According to the official Indications and Usage listed in regulatory documents, Vaxigel is specifically indicated for the treatment of diagnosed vaginal infections.

It is not officially indicated or recognized in regulatory documents as a preventative measure against future infections.


Q: Can Vaxigel be used by people who are sensitive to other medications?

The official contraindications only strictly prohibit use by people with a known hypersensitivity to Metronidazole, Nystatin, or related compounds.

General sensitivity to other, unrelated medications is a factor that may be discussed with a prescribing doctor before starting therapy.


Q: Can Vaxigel be stored outside of the refrigerator once opened?

The official product information specifies that Vaxigel must be stored at or below 30 C and protected from light, meaning it should not be stored in a refrigerator unless otherwise instructed.

After opening, the product must still be kept in its original container with the cap tightly closed to maintain stability and prevent contamination.


Q: Are there any known interactions between Vaxigel and common vitamins or supplements?

The major documented drug interactions, such as those with alcohol, Warfarin, and Lithium, are clearly noted in regulatory materials. However, interactions with most common vitamins or nutritional supplements are generally not listed in official product labeling.

It is generally advised that patients inform their healthcare provider about all supplements they are taking to prevent potential conflicts.


Q: Are there any specific activities to avoid immediately after using Vaxigel?

The official instructions for Vaxigel recommend applying the medication once daily, ideally before bedtime. This timing is specified to maximize the local retention and effectiveness of the gel.

While other activities are not strictly forbidden, following the bedtime instruction helps to ensure the patient can rest and allow the medication to work without being immediately cleared.

How should Vaxigel be stored and disposed of?

The official regulatory documents specify mandatory conditions for the storage and disposal of Vaxigel (Metronidazole/Nystatin Gel) to ensure stability and public safety.

Storage Requirements

Vaxigel must be stored at room temperature, defined as at or below 30°C (86°F), and must not be frozen. The product should be protected from light and kept in its original container, with the cap tightly closed when not in use. A critical safety requirement is to always keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Vaxigel should be disposed of through a drug take-back program or as advised by a pharmacist. It is essential not to flush the medicine down a sink or toilet or place it in household trash, as this is restricted by environmental guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vaxigel found in:

A-Z Index: